Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Desensitization to biological agents used in rheumatology
1
Department of Rheumatology, Medical University of Lodz, Poland
Submission date: 2020-01-08
Final revision date: 2020-02-10
Acceptance date: 2020-02-14
Online publication date: 2020-02-28
Publication date: 2020-02-28
Reumatologia 2020;58(1):26-33
KEYWORDS
TOPICS
ABSTRACT
Biological agents such as monoclonal antibodies and fusion proteins are widely used for the treatment of patients with various rheumatic disorders, influencing the quality of life, disability and even mortality in patients. However, biological agents can evoke adverse reactions of different grades of severity. Although drug avoidance remains a gold standard in the care of patients hypersensitive to medication, in certain clinical situations the culprit drug is the drug of choice and cannot be replaced by another equally effective compound. In such cases, desensitization can allow the patient to be treated within current guidelines and with the most effective treatment.
The authors searched Medline and Scopus databases for English-language sources using the following key words: hypersensitivity, desensitization, biologicals, adalimumab, etanercept, adalimumab, certolizumab, golimumab, rituximab, infliximab, ixekizumab, tocilizumab, anakinra and canakinumab.
The aim of our review is to present the current knowledge about desensitization to biological agents and some guidelines according to patient inclusion, contraindications, procedures, and safety requirements.
Drug desensitization is a new issue in rheumatology, and the solution to the problem of allergic reactions to biological drugs, which gives patients with rheumatic diseases the opportunity to extend and prolong their therapy. The present article is one of the first widely discussing this topic in the biological treatment of rheumatic diseases.
The authors searched Medline and Scopus databases for English-language sources using the following key words: hypersensitivity, desensitization, biologicals, adalimumab, etanercept, adalimumab, certolizumab, golimumab, rituximab, infliximab, ixekizumab, tocilizumab, anakinra and canakinumab.
The aim of our review is to present the current knowledge about desensitization to biological agents and some guidelines according to patient inclusion, contraindications, procedures, and safety requirements.
Drug desensitization is a new issue in rheumatology, and the solution to the problem of allergic reactions to biological drugs, which gives patients with rheumatic diseases the opportunity to extend and prolong their therapy. The present article is one of the first widely discussing this topic in the biological treatment of rheumatic diseases.
REFERENCES (56)
1.
Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am 2014; 34: 615-632, DOI: 10.1016/j.iac.2014.04.008.
2.
Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61: 912-920, DOI: 10.1111/j.1398-9995.2006.01058.x.
3.
Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract 2016; 4: 497-504, DOI: 10.1016/j.jaip.2015.12.019.
4.
Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy 2010; 65: 1357-1366, DOI: 10.1111/j.1398-9995.2010.02441.x.
5.
Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy 2014; 69: 420-437, DOI: 10.1111/all.12350.
6.
Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FceRI internalization. Eur J Immunol 2011; 41: 1004-1013, DOI: 10.1002/eji.201040810.
7.
Kowalski ML, Ansotegui I, Aberer W, et al. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J 2016; 9: 33, DOI: 10.1186/s40413-016-0122-3.
8.
Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124: 1259-1266, DOI: 10.1016/j.jaci.2009.09.009.
9.
Bavbek S, Aydin O, Ataman S, et al. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011; 66: 1256-1257, DOI: 10.1111/j.1398-9995.2011.02601.x.
10.
Bavbek S, Ataman S, Bankova L, Castells M. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation. Allergol Immunopathol (Madr) 2013; 41: 204-206, DOI: 10.1016/j.aller.2012.04.006.
11.
Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-37, DOI: 10.1097/00054725-200102000-00005.
12.
Lelong J, Duburque C, Fournier C, et al. Desensitisation to infliximab in patients with Crohn’s disease. Rev Mal Respir 2005; 22: 239-246, DOI: 10.1016/s0761-8425(05)85477-4.
13.
Vultaggio A, Nencini F, Bormioli S, et al. Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reaction. J Allergy Clin Immunol Pract 2020, DOI: 10.1016/j.jaip.2019.12.040.
14.
Mourad AA, Boktor MN, Yilmaz-Demirdag Y, Bahna SL. Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol 2015; 115: 143-146, DOI: 10.1016/j.anai.2015.06.004.
15.
Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013; 68: 853-861, DOI: 10.1111/all.12105.
16.
Gallardo R, Fobelo MJ, Pastor C, Orta-Cuevas JC. Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis. Farm Hosp 2010; 34: 94-96, DOI: 10.1016/j.farma.2009.10.001.
17.
Caimmi SM, Caimmi D, Riscassi S, Marseglia GL. A new pediatric protocol for rapid desensitization to monoclonal anti-bodies. Int Arch Allergy Immunol 2014; 165: 214-218, DOI: 10.1159/000369299.
18.
Behera SK, Selvarajan S, Mathews J, et al. A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis. Curr Drug Saf 2019; 14: 158-162, DOI: 10.2174/1574886314666190119115632.
19.
Bavbek S, Kendirlinan R, Çerçi P, et al. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics. Int Arch Allergy Immunol 2016; 171: 227-233, DOI: 10.1159/000454808.
20.
Yang BC, Castells MC. Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases. Ann Allergy Asthma Immunol 2019; 123: 11-15, DOI: 10.1016/j.anai.2019.03.008.
21.
Hall J, Findeisen J. Successful etanercept desensitization in a patient with severe injection site reactions. J Clin Rheumatol 2013; 19: 407-408, DOI: 10.1097/RHU.0b013e3182a705fe.
22.
Fellner MJ, Yohe N. Etanercept urticaria in a patient with psoriasis desensitized using a new method. J Drugs Dermatol 2013; 12: 1168-1169.
23.
de la Varga Martínez R, Gutiérrez Fernández D, Foncubierta Fernández A, et al. Rapid subcutaneous desensitization for treatment of hypersensitivity reactions to etanercept in two patients with positive basophil activation test. Allergol Int 2017; 66: 357-359, DOI: 10.1016/j.alit.2016.09.002.
24.
Bavbek S, Ataman Ş, Akinci A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 2015; 3: 629-632, DOI: 10.1016/j.jaip.2015.01.009.
25.
Thévenot J, Ferrier le Bouëdec MC, Buisson A, et al. Rapid Desensitization to Adalimumab Is Associated With Decreased Basophil Sensitivity. J Investig Allergol Clin Immunol 2019; 29: 141-143, DOI: 10.18176/jiaci.0350.
26.
Rodríguez-Jiménez B, Domínguez-Ortega J, González-Herrada C, et al. Successful adalimumab desensitization after generalized urticaria and rhinitis. J Investig Allergol Clin Immunol 2009; 19: 246-247.
27.
Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol 2011; 106: 547-548, DOI: 10.1016/j.anai. 2011.03.014.
28.
Gutiérrez Fernández D, Foncubierta Fernández A, Anguita Carazo JL, et al. Adalimumab desensitization protocol in a patient with a generalized urticarial reaction and angioedema following adalimumab administration. J Investig Allergol Clin Immunol 2014; 24: 273-275.
29.
Demirel F, Kartal O, Gulec M, et al. Desensitization to Adalimumab: An Example of Repeated Desensitization to a Biological Agent. Drug Saf Case Rep 2015; 2: 7, DOI: 10.1007/s40800-015-0008-2.
30.
Wong JT, Long A. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms. J Allergy Clin Immunol Pract 2017; 5: 1564-1571, DOI: 10.1016/j.jaip. 2017.08.004.
31.
Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122: 574-580, DOI: 10.1016/j.jaci.2008.02.044.
32.
Abadoglu O, Epozturk K, Atayik E, Kaptanoglu E. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option. J Investig Allergol Clin Immunol 2011; 21: 319-321.
33.
Kuo JC, Hawkins C, Yip D. Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions. Intern Med J 2014; 44: 442-449, DOI: 10.1111/imj.12320.
34.
Fajt ML, Petrov AA. Desensitization protocol for rituximab induced serum sickness. Curr Drug Saf 2014; 9: 240-242, DOI: 10.2174/1574886309666140509154056.
35.
Ataca P, Atilla E, Kendir R, et al. Successful desensitization of a patient with rituximab hypersensitivity. Case Reports Immunol 2015; 2015: 524507, DOI: 10.1155/2015/524507.
36.
Amoros-Reboredo P, Sanchez-Lopez J, Bastida-Fernandez C, et al. Desensitization to rituximab in a multidisciplinary setting. Int J Clin Pharm 2015; 37: 744-748, DOI: 10.1007/s11096-015-0136-x.
37.
Dilley MA, Lee JP, Platt CD, Broyles AD. Rituximab Desensitization in Pediatric Patients: Results of a Case Series. Pediatr Allergy Immunol Pulmonol 2016; 29: 91-94. DOI: 10.1089/ped.2015.0615.
38.
Lebel E, Ben-Yehuda D, Bohbot E, et al. Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions. J Allergy Clin Immunol Pract 2016; 4: 1000-1002, DOI: 10.1016/j.jaip.2016.05.013.
39.
Öztürk E, Özyiğit LP, Öztürk AB, et al. Rituximab desensitization in three patients with severe rituximab allergy. Curr Probl Cancer 2017; 41: 349-354, DOI: 10.1016/j.currproblcancer. 2017.07.003.
40.
Della-Torre E, Conti A, Berti A, et al. Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor. Int J Rheum Dis 2017; 20: 276-279, DOI: 10.1111/1756-185X.13021.
41.
Pérez-Rodríguez E, Martínez-Tadeo JA, Perez-Rodriguez N, et al. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol. J Allergy Clin Immunol Pract 2018; 6: 1621-1627 e6, DOI: 10.1016/j.jaip.2017.11.033.
42.
Görgülü B, Seval GC, Kendirlinan R, et al. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience. J Investig Allergol Clin Immunol 2019; 29: 468-470, DOI: 10.18176/jiaci.0445.
43.
Erdogan T, Yasar Bilge NS, Kasifoglu T. Successful slow tocilizumab desensitization in a patient with adult onset Still disease. Biologicals 2018; 55: 17-18, DOI: 10.1016/j.biologicals. 2018.07.002.
44.
Justet A, Neukirch C, Poubeau P, et al. Successful rapid tocilizumab desensitization in a patient with Still disease. J Allergy Clin Immunol Pract 2014; 2: 631-632, DOI: 10.1016/j.jaip.2014.04.015.
45.
Ye W, Fifield MC, Mayhew A, et al. Successful tocilizumab desensitization in an adult with juvenile idiopathic arthritis. Scand J Rheumatol 2016; 45: 75-76, DOI: 10.3109/03009742.2015. 1074279.
46.
Cansever M, Sahin N, Dursun I, et al. Successful Slow Desensitization to Tocilizumab in a 15-Year-Old Patient. J Investig Allergol Clin Immunol 2018; 28: 436-438, DOI: 10.18176/jiaci. 0314.
47.
Cortellini G, Mascella F, Simoncelli M, et al. Effective Desensitization to Tocilizumab in Delayed Hypersensitivity Reaction. Pharmacology 2018; 102: 114-116, DOI: 10.1159/000490419.
48.
Demir S, Gelincik A, Coskun R, et al. A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions. Ann Allergy Asthma Immunol 2019; 123: 394-397, DOI: 10.1016/j.anai.2019.07.031.
49.
Jimenez RB, Vera DG, Rivera-Diaz R, et al. Successful subcutaneous desensitization in a patient with allergy to ixekizumab. J Allergy Clin Immunol Pract 2018; 6: 1761-1762, DOI: 10.1016/j.jaip.2017.12.036.
50.
Leroy V, Lazaro E, Darrigade AS, et al. Successful rapid subcutaneous desensitization to anakinra in a case of delayed-type hypersensitivity reaction. Br J Dermatol 2016; 174: 1417-1418, DOI: 10.1111/bjd.14454.
51.
Şoyyiğit S, Kendirlinan R, Aydin O, Celik GE. Successful desensitization with anakinra in a case with immediate hypersensitivity reaction. Ann Allergy Asthma Immunol 2014; 113: 325-326, DOI: 10.1016/j.anai.2014.06.017.
52.
Mendonca LO, Malle L, Donovan FX, et al. Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN. J Clin Immunol 2017; 37: 445-451, DOI: 10.1007/s10875-017-0399-1.
53.
YIImaz I, Türk M, Nazik Bahçecioğlu S. Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction. Eur Ann Allergy Clin Immunol 2018; 50: 94-96, DOI: 10.23822/EurAnnACI. 1764-1489.30.
54.
Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012; 61: 1575-1584, DOI: 10.1007/s00262-012-1273-x.
55.
Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions – an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013; 68: 844-852, DOI: 10.1111/all.12161.
56.
Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 2009; 29: 585-606, DOI: 10.1016/j.iac.2009.04.012.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
